|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hashim D, Boffetta P, La Vecchia C, Rota
M4, Bertuccio P, Malvezzi M and Negri E: The global decrease in
cancer mortality: Trends and disparities. Ann Oncol. 27:926–933.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zahonero C, Sepúlveda JM and Sánchez-Gómez
P: Epidermic growth factor receptor (EGFR) in glioblastomas: the
mechanism of tumorigenesis and its role as a therapeutic target.
Rev Neurol. 61:85–93. 2015.(In Spanish). PubMed/NCBI
|
|
5
|
Weber KL, Doucet M, Price JE, Baker C, Kim
SJ and Fidler IJ: Blockade of epidermal growth factor receptor
signaling leads to inhibition of renal cell carcinoma growth in the
bone of nude mice. Cancer Res. 63:2940–2947. 2003.PubMed/NCBI
|
|
6
|
Mendelsohn J: The epidermal growth factor
receptor as a target for cancer therapy. Endocr Relat Cancer.
8:3–9. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu Y, Liu H, Shi X and Song Y: Can EGFR
mutations in plasma or serum be predictive markers of
non-small-cell lung cancer? A meta-analysis. Lung Cancer.
88:246–253. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee HJ, Seo AN, Kim EJ, Jang MH, Kim YJ,
Kim JH, Kim SW, Ryu HS, Park IA, Im SA, et al: Prognostic and
predictive values of EGFR overexpression and EGFR copy number
alteration in HER2-positive breast cancer. Br J Cancer.
112:103–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nagatsuma AK, Aizawa M, Kuwata T, Doi T,
Ohtsu A, Fujii H and Ochiai A: Expression profiles of HER2, EGFR,
MET and FGFR2 in a large cohort of patients with gastric
adenocarcinoma. Gastric Cancer. 18:227–238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weber DC, Tille JC, Combescure C, Egger
JF, Laouiti M, Hammad K, Granger P, Rubbia-Brandt L and Miralbell
R: The prognostic value of expression of HIF1α, EGFR and VEGF-A, in
localized prostate cancer for intermediate- and high-risk patients
treated with radiation therapy with or without androgen deprivation
therapy. Radiat Oncol. 7:662012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Numico G, Russi EG, Colantonio I, Lantermo
RA, Silvestris N, Vitiello R, Comino A, Abrate M, Zavattero C,
Melano A, et al: EGFR status and prognosis of patients with locally
advanced head and neck cancer treated with chemoradiotherapy.
Anticancer Res. 30:671–676. 2010.PubMed/NCBI
|
|
12
|
Normanno N, Maiello MR and De Luca A:
Epidermal growth factor receptor tyrosine kinase inhibitors
(EGFR-TKIs): Simple drugs with a complex mechanism of action? J
Cell Physiol. 194:13–19. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ayyappan S, Prabhakar D and Sharma N:
Epidermal growth factor receptor (EGFR)-targeted therapies in
esophagogastric cancer. Anticancer Res. 33:4139–4155.
2013.PubMed/NCBI
|
|
14
|
Jiang C, Chen X, Alattar M, Wei J and Liu
H: MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis
of gastric cancer. Cancer Gene Ther. 22:291–301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang QX, Zhu YQ, Zhang H and Xiao J:
Altered miRNA expression in gastric cancer: A systematic review and
meta-analysis. Cell Physiol Biochem. 35:933–944. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang XT, Zhang Z, Xin YN, Ma XZ and Xuan
SY: Impairment of growth of gastric carcinoma by miR-133-mediated
Her-2 inhibition. Tumour Biol. 36:8925–8930. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie J, Chen M, Zhou J, Mo MS, Zhu LH, Liu
YP, Gui QJ, Zhang L and Li GQ: miR-7 inhibits the invasion and
metastasis of gastric cancer cells by suppressing epidermal growth
factor receptor expression. Oncol Rep. 31:1715–1722.
2014.PubMed/NCBI
|
|
18
|
Han C, Zhou Y, An Q, Li F, Li D, Zhang X,
Yu Z, Zheng L, Duan Z and Kan Q: MicroRNA-1 (miR-1) inhibits
gastric cancer cell proliferation and migration by targeting MET.
Tumour Biol. 36:6715–6723. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zheng Z, Yan D, Chen X, Huang H, Chen K,
Li G, Zhou L, Zheng D, Tu L and Dong XD: MicroRNA-206: Effective
inhibition of gastric cancer progression through the c-Met pathway.
PLoS One. 10:e01287512015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Peng Y, Guo JJ, Liu YM and Wu XL:
MicroRNA-34A inhibits the growth, invasion and metastasis of
gastric cancer by targeting PDGFR and MET expression. Biosci Rep.
34:pii: e001122014. View Article : Google Scholar
|
|
21
|
Liu J, Xue H, Zhang J, Suo T, Xiang Y,
Zhang W, Ma J, Cai D and Gu X: MicroRNA-144 inhibits the metastasis
of gastric cancer by targeting MET expression. J Exp Clin Cancer
Res. 34:352015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tsai MM, Wang CS, Tsai CY, Chen CY, Chi
HC, Tseng YH, Chung PJ, Lin YH, Chung IH, Chen CY, et al:
MicroRNA-196a/-196b promote cell metastasis via negative regulation
of radixin in human gastric cancer. Cancer Lett. 351:222–231. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
An Y, Zhang Z, Shang Y, Jiang X, Dong J,
Yu P, Nie Y and Zhao Q: miR-23b-3p regulates the chemoresistance of
gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis.
6:e17662015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou L, Qiu T, Xu J, Wang T, Wang J, Zhou
X, Huang Z, Zhu W, Shu Y and Liu P: miR-135a/b modulate cisplatin
resistance of human lung cancer cell line by targeting MCL1. Pathol
Oncol Res. 19:677–683. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Giehl K, Skripczynski B, Mansard A, Menke
A and Gierschik P: Growth factor-dependent activation of the
Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell
line PANC-1 carrying activated K-ras: Implications for cell
proliferation and cell migration. Oncogene. 19:2930–2942. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Troiani T, Napolitano S, Vitagliano D,
Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello
F and Martinelli E: Primary and acquired resistance of colorectal
cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway
activation and can be overcome by combined MEK/EGFR inhibition.
Clin Cancer Res. 20:3775–3786. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Davis NM, Sokolosky M, Stadelman K, Abrams
SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro
A, et al: Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in
breast cancer: Possibilities for therapeutic intervention.
Oncotarget. 5:4603–4650. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lim HJ, Crowe P and Yang JL: Current
clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment
of human cancer. J Cancer Res Clin Oncol. 141:671–689. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang L and Fu L: Mechanisms of resistance
to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 5:390–401.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu N, Wang SQ, Tan D, Gao Y, Lin G and Xi
R: EGFR, Wingless and JAK/STAT signaling cooperatively maintain
Drosophila intestinal stem cells. Dev Biol. 354:31–43. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Janmaat ML and Giaccone G: The epidermal
growth factor receptor pathway and its inhibition as anticancer
therapy. Drugs Today (Barc). 39 Suppl C:61–80. 2003.PubMed/NCBI
|
|
32
|
Lordick F, Kang YK, Chung HC, Salman P, Oh
SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et
al: Arbeitsgemeinschaft Internistische Onkologie and EXPAND
Investigators: Capecitabine and cisplatin with or without cetuximab
for patients with previously untreated advanced gastric cancer
(EXPAND): A randomised, open-label phase 3 trial. Lancet Oncol.
14:490–499. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Waddell T, Chau I, Cunningham D, Gonzalez
D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G,
Wadsley J, et al: Epirubicin, oxaliplatin, and capecitabine with or
without panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): A randomised, open-label phase 3
trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang WP, Wang KN, Gao Q and Chen LQ: Lack
of EGFR mutations benefiting gefitinib treatment in adenocarcinoma
of esophagogastric junction. World J Surg Oncol. 10:142012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dragovich T, McCoy S, Fenoglio-Preiser CM,
Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS,
Blanke CD, et al: Phase II trial of erlotinib in gastroesophageal
junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol.
24:4922–4927. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cappetta A, Lonardi S, Pastorelli D,
Bergamo F, Lombardi G and Zagonel V: Advanced gastric cancer (GC)
and cancer of the gastro-oesophageal junction (GEJ): Focus on
targeted therapies. Crit Rev Oncol Hematol. 81:38–48.
2012.PubMed/NCBI
|
